Press release
Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in The Hague, Netherlands on February 5 - 7, 2020. Johnny Mahlangu, M.B. B.Ch., M.Med., F.C.Path., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator in the Dalcinonacog Alfa (DalcA) Phase 2b clinical trial will deliver the oral presentation.\n Oral Presentation details Presentation Title:Phase 2b Trial to Evaluate the Safety and Factor IX Levels Resulting from a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacog Alfa (DalcA) in Hemophilia BPresenter:Dr. Johnny Mahlangu, principal investigator in the DalcA trialSession:SLAM: OR07Date/Time:Friday, February 7, 2020 at 8:30 am – 10:00 am CET Poster presentation details Poster Title:Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Ascending Doses of Subcutaneous Marzeptacog Alfa (Activated) (MarzAA) in Adult Subjects with HemophiliaPresenter:Linda Neuman, M.D., M.B.A., vice president, clinical developmentSession/Poster:Poster Session / P128Date/Time:Wednesday, February 5 - Friday, February 7, 2020 Presentation February 5th between 18:30-19:30 Poster Title:Subcutaneous Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia A Mice Submitted to a Tail Clip InjuryPresenter:Grant Blouse, Ph.D., vice president, translational researchSession/Poster:Poster Session / P036Date/Time:Wednesday, February 5 - Friday, February 7, 2020: Presentation February 5th between 18:30-19:30 Poster Title:Hemophilia B Gene Therapy in Mice Using a Novel Chimeric AAV Capsid Combined with the Potency Enhanced CB 2679d-GT FIX VariantPresenter:Grant Blouse, Ph.D., vice president, translational researchSession/Poster:Poster Session / P030Date/Time:Wednesday, February 5 - Friday, February 7, 2020 Presentation February 5th between 18:30-19:30 Abstracts will be available on the EAHAD website a week before the meeting begins. A copy of the presentation materials can be accessed on the Events and Presentations section of the Catalyst website (www.catalystbioscien...